SNX29 and neoplasm: The results showed that the SNX29 gene was significantly associated with the sensitivity of various tumor cell lines to nine antitumor drugs, including vorinostat, 7-hydroxystaurosporine, idelalisib, cabozantinib, calusterone, vismodegib, perifosine, rapamycin and panobinostat.